0.00
+0(+0.00%)
Currency In USD
Address
620 Memorial Drive
Cambridge, MA 02139
United States of America
Phone
617 577 0300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
66
First IPO Date
May 08, 2018
| Name | Title | Pay | Year Born |
| Dr. Duncan McHale M.D., MBBS, Ph.D. | Chief Medical Officer | 661,968 | 1967 |
| Mr. Douglas Maslin | Senior Director & Immunology Clinical Lead | 0 | N/A |
| Mr. Craig R. Jalbert CIRA | President, Secretary, Principal Executive, Financial and Accounting Officer & Director | 0 | 1962 |
| Dr. Andrea Itano Ph.D. | Head of Research | 0 | N/A |
| Ms. Leslie Wardwell-Scott Ph.D. | Vice President and Head of Corporate Development & Strategic Integration | 0 | N/A |
| Dr. Chun Zhang Ph.D. | Chief Technical Operations & Quality Officer | 0 | N/A |
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.